{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:56:00Z","timestamp":1771955760452,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T00:00:00Z","timestamp":1622592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s43032-021-00622-2","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T18:48:58Z","timestamp":1622659738000},"page":"3390-3396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gonadotropin-Releasing Hormone Agonist Versus Recombinant Human Chorionic Gonadotropin Triggering in Fertility Preservation Cycles"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9930-0051","authenticated-orcid":false,"given":"Einat Haikin","family":"Herzberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabaa","family":"Knaneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadar","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adi","family":"Reches","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalit","family":"Ben-Yosef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Kalma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foad","family":"Azem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nivin","family":"Samara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"622_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fendo.2019.00094","volume":"10","author":"FM Ubaldi","year":"2019","unstructured":"Ubaldi FM, Cimadomo D, Vaiarelli A, Fabozzi G, Venturella R, Maggiulli R, et al. Advanced maternal age in IVF: still a challenge? The Present and the Future of Its Treatment. Front Endocrinol (Lausanne). 2019;10:94. https:\/\/doi.org\/10.3389\/fendo.2019.00094.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"622_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JOP.18.00160","volume":"14","author":"K Oktay","year":"2018","unstructured":"Oktay K, Harvey BE, Loren AW. Fertility preservation in patients with cancer: ASCO clinical practice guideline update summary. J Oncol Pract. 2018;14(6):381\u20135. https:\/\/doi.org\/10.1200\/JOP.18.00160.","journal-title":"J Oncol Pract"},{"issue":"2","key":"622_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/humupd\/dmw038","volume":"23","author":"L Rienzi","year":"2017","unstructured":"Rienzi L, Gracia C, Maggiulli R, LaBarbera AR, Kaser DJ, Ubaldi FM, et al. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017;23(2):139\u201355. https:\/\/doi.org\/10.1093\/humupd\/dmw038.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"622_CR4","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/humrep\/deh765","volume":"20","author":"P Humaidan","year":"2005","unstructured":"Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF\/ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20(5):1213\u201320. https:\/\/doi.org\/10.1093\/humrep\/deh765.","journal-title":"Hum Reprod"},{"issue":"5","key":"622_CR5","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/humrep\/dei475","volume":"21","author":"R Babayof","year":"2006","unstructured":"Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006;21(5):1260\u20135. https:\/\/doi.org\/10.1093\/humrep\/dei475.","journal-title":"Hum Reprod"},{"key":"622_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008046.pub4","volume":"10","author":"MA Youssef","year":"2014","unstructured":"Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;10:CD008046. https:\/\/doi.org\/10.1002\/14651858.CD008046.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"622_CR7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/humupd\/8.6.559","volume":"8","author":"A Delvigne","year":"2002","unstructured":"Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8(6):559\u201377. https:\/\/doi.org\/10.1093\/humupd\/8.6.559.","journal-title":"Hum Reprod Update"},{"issue":"4","key":"622_CR8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3109\/09513599609012319","volume":"10","author":"A Weissman","year":"1996","unstructured":"Weissman A, Lurie S, Zalel Y, Goldchmit R, Shoham Z. Human chorionic gonadotropin: pharmacokinetics of subcutaneous administration. Gynecol Endocrinol. 1996;10(4):273\u20136. https:\/\/doi.org\/10.3109\/09513599609012319.","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"622_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.fertnstert.2007.11.049","volume":"91","author":"D Bodri","year":"2009","unstructured":"Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91(2):365\u201371. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.11.049.","journal-title":"Fertil Steril"},{"issue":"1","key":"622_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","volume":"89","author":"L Engmann","year":"2008","unstructured":"Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89(1):84\u201391. https:\/\/doi.org\/10.1016\/j.fertnstert.2007.02.002.","journal-title":"Fertil Steril"},{"issue":"3","key":"622_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.rbmo.2014.05.008","volume":"29","author":"P Humaidan","year":"2014","unstructured":"Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? Reprod BioMed Online. 2014;29(3):274\u201380. https:\/\/doi.org\/10.1016\/j.rbmo.2014.05.008.","journal-title":"Reprod BioMed Online"},{"issue":"3","key":"622_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.fertnstert.2011.12.020","volume":"97","author":"L Engmann","year":"2012","unstructured":"Engmann L, Benadiva C. Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. Fertil Steril. 2012;97(3):531\u20133. https:\/\/doi.org\/10.1016\/j.fertnstert.2011.12.020.","journal-title":"Fertil Steril"},{"issue":"3","key":"622_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.fertnstert.2015.06.011","volume":"104","author":"L Meyer","year":"2015","unstructured":"Meyer L, Murphy LA, Gumer A, Reichman DE, Rosenwaks Z, Cholst IN. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles. Fertil Steril. 2015;104(3):637\u201342. https:\/\/doi.org\/10.1016\/j.fertnstert.2015.06.011.","journal-title":"Fertil Steril"},{"issue":"5","key":"622_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.fertnstert.2016.06.013","volume":"106","author":"FE Chang","year":"2016","unstructured":"Chang FE, Beall SA, Cox JM, Richter KS, DeCherney AH, Levy MJ. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response. Fertil Steril. 2016;106(5):1093\u2013100 e3. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.06.013.","journal-title":"Fertil Steril"},{"issue":"5","key":"622_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/humrep\/des049","volume":"27","author":"SL Chen","year":"2012","unstructured":"Chen SL, Ye DS, Chen X, Yang XH, Zheng HY, Tang Y, et al. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol. Hum Reprod. 2012;27(5):1351\u20136. https:\/\/doi.org\/10.1093\/humrep\/des049.","journal-title":"Hum Reprod"},{"issue":"2","key":"622_CR16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.fertnstert.2010.09.009","volume":"95","author":"BS Shapiro","year":"2011","unstructured":"Shapiro BS, Daneshmand ST, Restrepo H, Garner FC, Aguirre M, Hudson C. Efficacy of induced luteinizing hormone surge after \u201ctrigger\u201d with gonadotropin-releasing hormone agonist. Fertil Steril. 2011;95(2):826\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.09.009.","journal-title":"Fertil Steril"},{"issue":"5","key":"622_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/humrep\/dex027","volume":"32","author":"RJ Rodgers","year":"2017","unstructured":"Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Hum Reprod. 2017;32(5):1033\u201345. https:\/\/doi.org\/10.1093\/humrep\/dex027.","journal-title":"Hum Reprod"},{"issue":"3","key":"622_CR18","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.rbmo.2015.12.007","volume":"32","author":"L Engmann","year":"2016","unstructured":"Engmann L, Benadiva C, Humaidan P. GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reprod BioMed Online. 2016;32(3):274\u201385. https:\/\/doi.org\/10.1016\/j.rbmo.2015.12.007.","journal-title":"Reprod BioMed Online"},{"issue":"9","key":"622_CR19","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/humrep\/det304","volume":"28","author":"S Iliodromiti","year":"2013","unstructured":"Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, et al. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Hum Reprod. 2013;28(9):2529\u201336. https:\/\/doi.org\/10.1093\/humrep\/det304.","journal-title":"Hum Reprod"},{"issue":"3","key":"622_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10815-019-01646-z","volume":"37","author":"R Makhijani","year":"2020","unstructured":"Makhijani R, Thorne J, Bartels C, Bartolucci A, Nulsen J, Grow D, et al. Pregnancy outcomes after frozen-thawed single euploid blastocyst transfer following IVF cycles using GNRH agonist or HCG trigger for final oocyte maturation. J Assist Reprod Genet. 2020;37(3):611\u20137. https:\/\/doi.org\/10.1007\/s10815-019-01646-z.","journal-title":"J Assist Reprod Genet"},{"issue":"2","key":"622_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.fertnstert.2019.03.040","volume":"112","author":"J Thorne","year":"2019","unstructured":"Thorne J, Loza A, Kaye L, Nulsen J, Benadiva C, Grow D, et al. Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin. Fertil Steril. 2019;112(2):258\u201365. https:\/\/doi.org\/10.1016\/j.fertnstert.2019.03.040.","journal-title":"Fertil Steril"},{"issue":"2","key":"622_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.rbmo.2011.11.001","volume":"24","author":"P Humaidan","year":"2012","unstructured":"Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, et al. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod BioMed Online. 2012;24(2):134\u201341. https:\/\/doi.org\/10.1016\/j.rbmo.2011.11.001.","journal-title":"Reprod BioMed Online"},{"issue":"7","key":"622_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10815-014-0248-6","volume":"31","author":"J Reddy","year":"2014","unstructured":"Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet. 2014;31(7):927\u201332. https:\/\/doi.org\/10.1007\/s10815-014-0248-6.","journal-title":"J Assist Reprod Genet"},{"issue":"3","key":"622_CR24","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.fertnstert.2017.06.027","volume":"108","author":"N Pereira","year":"2017","unstructured":"Pereira N, Kelly AG, Stone LD, Witzke JD, Lekovich JP, Elias RT, et al. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation. Fertil Steril. 2017;108(3):532\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.06.027.","journal-title":"Fertil Steril"},{"issue":"4","key":"622_CR25","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1210\/jc.2015-3878","volume":"101","author":"J Kim","year":"2016","unstructured":"Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab. 2016;101(4):1364\u201371. https:\/\/doi.org\/10.1210\/jc.2015-3878.","journal-title":"J Clin Endocrinol Metab"},{"key":"622_CR26","doi-asserted-by":"publisher","first-page":"100049","DOI":"10.1016\/j.eurox.2019.100049","volume":"4","author":"C Sonigo","year":"2019","unstructured":"Sonigo C, Sermondade N, Calvo J, Benard J, Sifer C, Grynberg M. Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients. Eur J Obstet Gynecol Reprod Biol X. 2019;4:100049. https:\/\/doi.org\/10.1016\/j.eurox.2019.100049.","journal-title":"Eur J Obstet Gynecol Reprod Biol X"},{"issue":"1","key":"622_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12958-018-0443-x","volume":"17","author":"O Goldrat","year":"2019","unstructured":"Goldrat O, Van Den Steen G, Gonzalez-Merino E, Dechene J, Gervy C, Delbaere A, et al. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers. Reprod Biol Endocrinol. 2019;17(1):3. https:\/\/doi.org\/10.1186\/s12958-018-0443-x.","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"622_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/09513590802404013","volume":"25","author":"A Galindo","year":"2009","unstructured":"Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol. 2009;25(1):60\u20136. https:\/\/doi.org\/10.1080\/09513590802404013.","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"622_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.rbmo.2009.06.001","volume":"19","author":"M Melo","year":"2009","unstructured":"Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod BioMed Online. 2009;19(4):486\u201392. https:\/\/doi.org\/10.1016\/j.rbmo.2009.06.001.","journal-title":"Reprod BioMed Online"},{"issue":"5","key":"622_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10815-009-9326-6","volume":"26","author":"A Sismanoglu","year":"2009","unstructured":"Sismanoglu A, Tekin HI, Erden HF, Ciray NH, Ulug U, Bahceci M. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial. J Assist Reprod Genet. 2009;26(5):251\u20136. https:\/\/doi.org\/10.1007\/s10815-009-9326-6.","journal-title":"J Assist Reprod Genet"},{"issue":"12","key":"622_CR31","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1093\/humrep\/dey321","volume":"33","author":"A Cobo","year":"2018","unstructured":"Cobo A, Garcia-Velasco J, Domingo J, Pellicer A, Remohi J. Elective and onco-fertility preservation: factors related to IVF outcomes. Hum Reprod. 2018;33(12):2222\u201331. https:\/\/doi.org\/10.1093\/humrep\/dey321.","journal-title":"Hum Reprod"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-021-00622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-021-00622-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-021-00622-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T19:42:39Z","timestamp":1636573359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-021-00622-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,2]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1007\/s43032-021-00622-2","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,2]]},"assertion":[{"value":"1 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}